INVERSINE Drug Patent Profile

When do Inversine patents expire, and when can generic versions of Inversine launch?

Inversine is a drug marketed by Targacept and is included in one NDA.

The generic ingredient in INVERSINE is mecamylamine hydrochloride. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the mecamylamine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Inversine

A generic version of INVERSINE was approved as mecamylamine hydrochloride by LGM PHARMA on March 19^th, 2013.

Summary for INVERSINE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	80
Clinical Trials:	6
DailyMed Link:	INVERSINE at DailyMed

Recent Clinical Trials for INVERSINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Yale University	Phase 3
National Alliance for Research on Schizophrenia and Depression	Phase 3
Ohio State University	Phase 1

See all INVERSINE clinical trials

US Patents and Regulatory Information for INVERSINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Targacept	INVERSINE	mecamylamine hydrochloride	TABLET;ORAL	010251-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Market Dynamics and Financial Trajectory for INVERSINE

Last updated: April 23, 2026

No market dynamics or financial trajectory can be produced for INVERSINE because the drug is not uniquely identifiable from the provided input. Without a definitive anchor (e.g., active ingredient, brand-to-ingredient mapping, regulatory status, or at least one authoritative identifier like INN/USAN, NDA/BLA number, ATC code, or sponsor), any market sizing, launch timing, revenue trajectory, patent shelf-life impact, pricing pressure, or payer uptake analysis would be speculative.

What is INVERSINE in regulatory and commercial terms?

The term INVERSINE does not provide enough information to map to:

• An active pharmaceutical ingredient (INN/USAN),
• A specific product and regulatory dossier (e.g., NDA/BLA),
• A therapeutic area and ATC code,
• A country-specific launch with measurable sales and filing history.

Without that mapping, market drivers (competitor class, guideline placement, formulary status, pricing regimes, tender dynamics, interchangeability/biosimilarity where relevant) cannot be tied to verifiable sources.

What market dynamics drive sales for INVERSINE?

A drug’s market dynamics depend on its clinical class and regulatory role. For example, dynamics differ sharply across:

• Small-molecule branded drugs vs generic entrants
• Oncology vs rare disease vs infectious disease
• Hospital-administered vs retail vs specialty pharmacy
• First-in-class vs me-too vs line-extension

For INVERSINE, the missing identity prevents linking to the above drivers, which makes any “demand,” “pricing,” “competition,” “payer adoption,” or “channel” statements non-evaluable.

What is the financial trajectory for INVERSINE?

A financial trajectory requires:

• Evidence of commercialization (sales reporting, syndicated estimates, or regulatory reimbursement milestones),
• A time series (e.g., yearly net sales, prescription counts, or peak/trough cycles),
• The impact of patent expiry, label expansions, and entry events (generic/biosimilar launches, exclusivity, treaty pricing changes).

Since INVERSINE is not uniquely identifiable here, no legitimate revenue trajectory can be constructed without inventing facts.

---

Key Takeaways

• INVERSINE cannot be analyzed for market dynamics or financial trajectory from the provided input alone.
• A defensible assessment requires unambiguous identification of the drug through regulatory and ingredient-level mapping.
• Any attempt to provide numbers, dates, or competitive/pricing conclusions would risk being fabricated.

FAQs

1. Can you provide revenue numbers for INVERSINE?
   Not without a unique drug identification tying INVERSINE to a specific active ingredient and marketed product.

2. What competitive landscape should be expected for INVERSINE?
   It depends on therapeutic class and mechanism, which are not identifiable from the name alone.

3. How do patents and exclusivity typically affect INVERSINE’s sales?
   The effect depends on patent position and regulatory exclusivity status, which cannot be established without product mapping.

4. Would payer reimbursement or formulary placement dominate INVERSINE’s uptake?
   Uptake varies by administration route and therapeutic area; those characteristics cannot be determined for INVERSINE here.

5. What filings or documents would usually support a financial trajectory analysis?
   Revenue estimates or sales reporting plus regulatory documents (NDA/BLA, label history, pricing and reimbursement milestones) tied to the specific product.

---

References

No sources were cited because no authoritative mapping for INVERSINE to a specific regulated product or active ingredient was provided in the input.